• Health Catalyst

  Participated · Series E · Feb 2016

  Health Catalyst provides a data warehouse and application development platform (Health Catalyst Data Operating System, DOS™) and professional services to help health systems and physician practices improve quality, efficiency and lower costs. Its DOS is powered by data from more than 100 million patients and over 1 trillion facts and supports applications and analytics for care delivery and patient engagement. The company offers applications such as Touchstone™ (benchmarking and prioritization powered by AI) and the Patient Safety Monitor™ Suite (predictive and text analytics with clinician review). Health Catalyst also acquired Medicity, a population health management company, adding more than 50 clients across HIEs, employers, plans, systems and providers. Headquartered in Silicon Slopes, Utah and led by CEO Dan Burton, the company bundles technology and services to support healthcare transformation. It intends to use new financing to continue expanding its technology and services offerings. Health Catalyst provides data warehousing, analytics and outcomes-improvement solutions to healthcare organizations of all sizes. Led by CEO Dan Burton and based in Salt Lake City, Utah, the company supports clinical, financial, and operational reporting and analysis needed for population health and accountable care. Following adoption of value-based reimbursement models, Health Catalyst is evolving from an offline data aggregator and analysis company to a real-time data production and decision-support company. It integrates knowledge derived from its data content and analytics into clients' decision workflows and their patients, accessible anywhere and on any device. The company intends to use the funds to expand its outcomes-improvement solutions and expects to release new solutions for activity-based costing, care management, and real-time clinical decision support this year. It recently closed a $70M Series E funding round. Health Catalyst is a Salt Lake City-based company that builds data warehousing and analytics software for healthcare organizations. Its platform is used to store and analyze clinical and operational data and the company plans to produce "content-driven clinical applications." Health Catalyst said it will invest $50 million in product development over the next 24 months to build those applications. The company reported bookings had increased fivefold year-over-year and expects to see positive cash flows during the calendar year. Customers named in the article include Crystal Run Healthcare, Kaiser Permanente, Memorial Hospital in Gulfport, and NorthBay Healthcare. Venture investors including Sequoia Capital, Norwest Venture Partners, Kaiser Permanente Ventures, Sorenson Capital, CHV Capital and Partners Healthcare participated in the recent financing. Health Catalyst provides a data warehousing platform and analytics suite built specifically for the healthcare industry to organize, visualize and utilize data from electronic health records. Its software integrates with EHRs like Cerner and Epic to give providers realtime visibility, drill-down analytics, segmentation and alerts for cost discrepancies and declining quality of care. The platform enables clinicians to drill into patient histories to inform treatments and prescriptions and to set up alerts that surface quality and cost issues. The five-year-old company says its software has been adopted by over 80 hospitals across the U.S., collectively impacting more than 20 million patients. Financially, it recently increased its Series B by $8 million to bring the round to $41 million, with participation from Norwest Venture Partners, Sequoia Capital, Sorenson Capital, Kaiser Permanente Ventures and CHV Capital. Health Catalyst positions itself to benefit from mandated transitions to digital health records under Obamacare, arguing hospitals will need agile, cloud-ready data warehouses and analytics to realize value from EHRs. Health Catalyst offers an agile, healthcare-specific data warehousing platform designed to integrate and analyze complex operational, financial, clinical and research data stored in EHRs. Its Adaptive Data Warehousing platform and more than 40 integrated products are deployed at 81 hospitals caring for over 20 million patients, including Allina Health, Indiana University Health, MultiCare Health System, North Memorial, Providence Health & Services, Stanford Hospital and Clinics, and Texas Children’s Hospital. The company has more than doubled in size in each of the past three years and expanded its product line from eight stand‑alone solutions to a platform of 40+ products. A majority of existing clients have dramatically expanded their relationships after rapid return on investment. Health Catalyst says its platform helps hospitals measure quality outcomes, meet regulatory and financial incentive reporting requirements, standardize best practices, and eliminate waste, driving millions of dollars in cost savings through reductions in length of stay, readmissions, unnecessary procedures and patient injury. Management plans to use the new funding to continue investing in technology, services, and people to support clients’ progression toward being data‑driven organizations.

• PerfectServe

  Participated · Equity · Sep 2015

  PerfectServe provides a comprehensive, secure communication and collaboration platform for healthcare, anchored by its flagship solution, PerfectServe Synchrony. Synchrony unites physicians, nurses and other care team members across the continuum and automatically identifies and provides immediate access to the right care team member to facilitate timely interaction. More than 100,000 clinicians at organizations such as Advocate Healthcare, Ascension Health, Covenant Medical Group, Hoag, MemorialCare Health System, Orlando Health, St. Joseph Health, and WellStar rely on PerfectServe. The company says it will use the $21 million financing to advance research and development of Synchrony and bring the product’s full set of capabilities to market. Management positions the funding to expand platform capabilities to meet growing demand for secure, communication-driven workflows and to improve care coordination, patient experience, and outcomes. Headquartered in Knoxville, Tennessee, PerfectServe has been serving healthcare provider organizations since 2000. PerfectServe offers a clinical communication platform designed to connect clinicians and push relevant clinical information to the right physician. Led by president and CEO Terry Edwards, the company processes more than 30 million transactions annually. It connects more than 20,000 physicians in health systems and medical practices across 154 U.S. markets. PerfectServe intends to use new funding to expand its national network of services and invest in innovations. The platform is positioned to improve clinician coordination and information delivery across a broad set of care settings.

• NeoChord

  Participated · Series C · Jun 2015

  NeoChord develops beating-heart mitral valve repair solutions for patients with mitral regurgitation. Its flagship product, the NeoChord Artificial Chordae Delivery System, enables a minimally invasive procedure on a beating heart without cardiopulmonary bypass or aortic cross-clamping and received CE market clearance in December 2012. In the United States the system is for investigational use only and is limited by federal law to investigational use. Founded in 2007 and led by President and CEO David Chung, the company is based in St. Louis Park, Minnesota. NeoChord plans to use the recent proceeds to accelerate development of its transcatheter chordal repair and edge-to-edge programs. Over the past 12 months the company has raised over $32m in equity. NeoChord is a medical technology company advancing beating-heart mitral valve repair, founded in 2007 by David Chung and based in St. Louis Park, Minnesota. Its flagship product, the NeoChord Artificial Chordae Delivery System (Model DS1000), enables minimally invasive transapical delivery of artificial chordae on a beating heart without cardiopulmonary bypass or aortic cross-clamp. The system received CE market clearance in December 2012 and in the United States is for investigational use only. The company intends to use the funds from the recent financing to accelerate development of its transcatheter chordal repair and edge-to-edge programs. The procedure provides real-time feedback that allows surgeons to precisely adjust chord length to reduce or eliminate mitral valve regurgitation while the heart is beating. David Chung serves as President and Chief Executive Officer. NeoChord, based in Eden Prairie, Minnesota and led by President & CEO David Chung, has developed a proprietary device enabling mitral valve repair on the beating heart using a minimally invasive approach. Its DS1000 device received CE marking in December 2012 for minimally invasive mitral valve repair via surgical implantation of artificial chordae tendinae. The company focuses on advancing clinical and regulatory work for its technology while pursuing commercialization. NeoChord closed a $20M Series C financing to support those efforts. The company will use the proceeds for clinical and regulatory advancements, sales and marketing, research and development, and working capital. The article does not report operating metrics such as revenue or user numbers. NeoChord is a medical technology company developing minimally invasive devices and procedures to treat mitral regurgitation. Its flagship DS1000 System, CE marked in December 2012, enables surgical implantation of artificial chordae tendinae and is approved for sale in Europe but is not available commercially in the United States. The company is also developing NeoNav imaging software and an Edge-to-Edge mitral valve technology; near-term clinical goals include completing enrollment in the TACT Registry and performing First-in-Man procedures for the Edge-to-Edge approach. NeoChord reports it is in-revenues in Europe, with initial reimbursement established in Germany and a rapidly growing queue of surgeons seeking training. Financially, the company completed a $3 million sale of Series B-2 Preferred Stock in March 2013 and later closed a $3 million credit facility, providing additional cash runway to pursue its clinical and product development milestones. The company is based in Eden Prairie, Minnesota. NeoChord is commercializing a minimally invasive cardiac surgery device that places artificial chords in the mitral valve to treat mitral regurgitation while the heart is beating. The procedure is designed to eliminate the need for sternotomy and cardiopulmonary bypass required in open heart surgery. NeoChord holds an exclusive license from the Mayo Clinic; the technology is currently approved only for clinical use. The company recently raised $5 million and is seeking an additional $6 million according to a regulatory filing. Management intends to use proceeds to secure European approval, prepare a U.S. investigational device exemption application, and fund the subsequent pivotal U.S. trial. Investors include Clarian Health Ventures, Heron Capital and TGap Ventures; the company is based in Minnesota.

• Par8o

  Participated · Series A · Jan 2015

  par8o offers an EMR-agnostic, cloud-based Healthcare Operating System that coordinates care delivery and plan design across providers, payers, and patients. The platform applies Pareto Optimization to help healthcare organizations optimize networks of providers and resources while balancing multiple constituencies. par8o's technology facilitates transitions in care, ensures information such as test results and discharge plans are available, and aims to streamline office workflows. Founded in 2012 by the physicians who created SERMO, par8o traces its roots to physician discussions around the Affordable Care Act. Customers include MGM Resorts, Harvard Medical School affiliated hospitals in Boston, and facilities within the Mount Sinai Health System, and every customer has expanded engagement after initial results. The company positions itself to address quality, communication, and cost pressures in healthcare by enabling continuous efficiency improvements without optimizing for a single party to the detriment of others.

• MedVentive

  Participated · Series D · Oct 2011

  MedVentive offers a fully integrated suite of web-based business and clinical intelligence and outreach applications to support population health, clinical integration, and provider-centered risk management. For more than a decade it has worked with provider and health plan organizations to deploy tools for quality intervention, pharmacy management, physician incentive programs, and point-of-care decision support. Its platform is built on a risk-adjusted data foundation and is used to engage physicians and optimize quality performance at both patient and population levels. The company positions itself as a leading provider of population and risk management solutions and seeks to meet market needs for clinical integration, population management, and management of financial risk. The recent financing was described by the company as validation of accelerating innovation and a strong market position. MedVentive is based in Waltham, Massachusetts. MedVentive is a Cambridge, MA-based supplier of integrated performance management solutions for health providers. Its core product is integrated performance management solutions aimed at healthcare providers. The company completed a $10M Series C financing to support growth. The proceeds will be used to accelerate the company’s next phase of product innovation. In August 2009 MedVentive announced it had raised $7.25M as part of this Series C. Following the financing, Enrico Petrillo, M.D. of Excel Venture Management joined the board and Caleb Winder of Excel became a board observer.

No current team members are available.